Template:Main Page News: Difference between revisions
From Embryology
mNo edit summary |
mNo edit summary |
||
| Line 1: | Line 1: | ||
{| width=700px| | {| width=700px| | ||
|-bgcolor="CEDFF2" | |-bgcolor="CEDFF2" | ||
| <span style="font-size:150%">'''News - | | <span style="font-size:150%">'''News - Thalidomide Molecular Mechanism shown in Zebrafish</span> | ||
|-bgcolor="F5FAFF" | |-bgcolor="F5FAFF" | ||
| valign=top|[[File: | | valign=top|[[File:Thalidomide destabilizes CD147.jpg|300px|left|alt=Thalidomide destabilizes CD147|link=Abnormal Development - Thalidomide]] | ||
PMID 27294876 | [http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.4128.html Nat Med.] | |||
Thalidomide (and derivatives lenalidomide and pomalidomide) are treatments for hematologic malignancies, multiple myeloma (MM) and del(5q) myelodysplastic syndrome (MDS). Cereblon (CRBN) is the primary target for both the anticancer and teratogenic effects, and it promotes the maturation of the CD147 ( [http://www.omim.org/entry/109480 OMIM - Basigin], BSG; a member of the immunoglobulin superfamily). | |||
Zebrafish knockdown of CD147 was shown to match the teratogenic effects of thalidomide exposure. | |||
:'''Links:''' [[Abnormal Development - Thalidomide]] | [[Zebrafish Development]] | |||
:'''Links:''' [[ | |||
|- | |- | ||
| | | | ||
:[[Template_talk:Main_Page_News|Older News Articles]] - [[Template_talk:Main_Page_News#January|Oral contraceptive no risk of major birth defects]] | [[Template_talk:Main_Page_News#September|Maternal Malaria Neurovascular Development Effects]] | [[Template_talk:Main_Page_News#June|Oocyte/Spermatozoa fate decision]] [[Template_talk:Main_Page_News#April|Rubella eliminated in the Americas]] | [[Template_talk:Main_Page_News#February|Three-person embryos]] | 2014 Nobel Prize in Medicine - [http://www.nobelprize.org/nobel_prizes/medicine/laureates/2014/press.html Neural Development] | [[Neural_-_Hippocampus_Development|Hippocampus Development]] | WHO - Trends in Maternal Mortality 1990 to 2013 - [[Statistics - Maternal Mortality]] | WHO polio - [[Abnormal Development - Polio Virus|Polio Virus]] | [[Template_talk:Main_Page_News#March|Trisomy 21 - Genome-wide Effects]] | :[[Template_talk:Main_Page_News|Older News Articles]] - [[Template_talk:Main_Page_News#March|Human pancreas stem cells show glycemic control in mice]] | [[Template_talk:Main_Page_News#January|Oral contraceptive no risk of major birth defects]] | [[Template_talk:Main_Page_News#September|Maternal Malaria Neurovascular Development Effects]] | [[Template_talk:Main_Page_News#June|Oocyte/Spermatozoa fate decision]] [[Template_talk:Main_Page_News#April|Rubella eliminated in the Americas]] | [[Template_talk:Main_Page_News#February|Three-person embryos]] | 2014 Nobel Prize in Medicine - [http://www.nobelprize.org/nobel_prizes/medicine/laureates/2014/press.html Neural Development] | [[Neural_-_Hippocampus_Development|Hippocampus Development]] | WHO - Trends in Maternal Mortality 1990 to 2013 - [[Statistics - Maternal Mortality]] | WHO polio - [[Abnormal Development - Polio Virus|Polio Virus]] | [[Template_talk:Main_Page_News#March|Trisomy 21 - Genome-wide Effects]] | ||
|}<noinclude>[[Category:Template]][[Category:2016]]</noinclude> | |}<noinclude>[[Category:Template]][[Category:2016]]</noinclude> | ||
Revision as of 14:07, 17 June 2016
| News - Thalidomide Molecular Mechanism shown in Zebrafish |
 PMID 27294876 | Nat Med. Thalidomide (and derivatives lenalidomide and pomalidomide) are treatments for hematologic malignancies, multiple myeloma (MM) and del(5q) myelodysplastic syndrome (MDS). Cereblon (CRBN) is the primary target for both the anticancer and teratogenic effects, and it promotes the maturation of the CD147 ( OMIM - Basigin, BSG; a member of the immunoglobulin superfamily). Zebrafish knockdown of CD147 was shown to match the teratogenic effects of thalidomide exposure. |
|
